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Elevated α-synuclein caused by SNCA gene triplication
impairs neuronal differentiation and maturation in
Parkinson's patient-derived induced pluripotent
stem cells
LMA Oliveira1,7, LJ Falomir-Lockhart1,8, MG Botelho1,9, K-H Lin2, P Wales3, JC Koch4, E Gerhardt3, H Taschenberger2,5, TF Outeiro3,5,
P Lingor4,5, B Schüle6, DJ Arndt-Jovin1 and TM Jovin*,1
We have assessed the impact of α-synuclein overexpression on the differentiation potential and phenotypic signatures of two
neural-committed induced pluripotent stem cell lines derived from a Parkinson's disease patient with a triplication of the human
SNCA genomic locus. In parallel, comparative studies were performed on two control lines derived from healthy individuals and
lines generated from the patient iPS-derived neuroprogenitor lines infected with a lentivirus incorporating a small hairpin RNA to
knock down the SNCA mRNA. The SNCA triplication lines exhibited a reduced capacity to differentiate into dopaminergic or
GABAergic neurons and decreased neurite outgrowth and lower neuronal activity compared with control cultures. This delayed
maturation phenotype was confirmed by gene expression profiling, which revealed a significant reduction in mRNA for genes
implicated in neuronal differentiation such as delta-like homolog 1 (DLK1), gamma-aminobutyric acid type B receptor subunit 2
(GABABR2), nuclear receptor related 1 protein (NURR1), G-protein-regulated inward-rectifier potassium channel 2 (GIRK-2) and
tyrosine hydroxylase (TH). The differentiated patient cells also demonstrated increased autophagic flux when stressed with
chloroquine. We conclude that a two-fold overexpression of α-synuclein caused by a triplication of the SNCA gene is sufficient to
impair the differentiation of neuronal progenitor cells, a finding with implications for adult neurogenesis and Parkinson’s disease
progression, particularly in the context of bioenergetic dysfunction.
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Parkinson’s disease (PD), the second most common neuro-
degenerative disorder, is characterized by impairment
of the motor system and associated non-motor clinical
manifestations.1 Age2 and exposure to environmental toxins3
constitute the most important non-genetic risk factors in the
development of sporadic disease. Neuronal loss is progres-
sive, primarily (but not exclusively) dopaminergic, and
accompanied by the accumulation of intracellular protein-
aceous inclusions known as Lewy bodies and Lewy neurites.4
α-Synuclein (aSyn) is the main protein constituent of these
inclusions5 and numerous findings attribute to it a central role
in the pathogenesis of PD.6–9 Both missense mutations
(p.A30P, p.E46K, p.H50Q,10 p.G51D,11 p.A53T, p.A53E12)
and increased copy number (duplication13 or triplication14) of
the SNCA gene encoding aSyn (PARK1/4 locus) cause early
onset autosomal dominant PD. In addition, multiple genome-
wide association studies have established that variations at
the SNCA locus contribute significantly to the etiology of
sporadic disease.15–17
The induced pluripotent stem cell (iPSC) technology offers a
unique and valuable tool for defining the early mechanisms
underlying PD and the development of early diagnostics and
new therapeutics.18–20 Cell lines have been generated from
fibroblasts obtained from patients with a variety of neurode-
generative diseases and neurons differentiated therefrom
reproduce specific features of those diseases in vitro.20
Comparisons between patient-derived and appropriately
selected healthy control lines are feasible, but unfortunately
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phenotypic differences unrelated to the disease mechanisms
arise due to the high clonal variability inherent in the
generation of iPSCs and differences in the genetic back-
ground of the iPSC lines.21–23 Lines manipulated by single
gene mutation have demonstrated the power of iPS technol-
ogy for disease modeling18–20 with possible therapeutic
potential.24,25
We have examined in this study the effects of increased
aSyn expression on the differentiation capacity and pheno-
typic signatures of two iPS clones derived from a patient with a
triplication of theSNCA gene, and compared themwith (i) lines
generated by lentiviral infection of the patient cells by an
shRNA construct targeting aSyn, and (ii) two control iPSC
lines one from an unaffected age-matched sibling26 and the
other from an unrelated healthy individual.27 All lines were
differentiated by defined protocols into neurons that exhibited
cardinal neuronal markers. These paradigms were used to
assess differentiation capacity, cell survival, neurite outgrowth
and electrophysiological properties. The results establish
aSyn-dosage as an important modulator of developmental
fitness of neuronal progenitor cells and support our previous
findings from studies of PD patient fibroblasts28 and neural-
committed induced pluripotent stem cells (NiPSCs) (including
the knockdown lines featured in this report)29 exposed to
toxins: (i) quantifiable reduction in viability under starvation
and stress and (ii) decreased mitochondrial function and
upregulated catabolism.
Results
Characterization and differentiation of iPSC-derived
NiPSCs. NiPSC neuroprogenitor lines PI-1754 (hereafter
designated SNCA_Tri, Clone 1 and Clone 2) were generated
from skin biopsy of an individual with a triplication of the
SNCA genomic locus resulting in early onset, autosomal
dominant PD.26,29 NiPSC line PI-1761 (control 1) was derived
from the mutation-negative, unaffected sister. An unrelated
NiPSC line, PI-1815-C7 (control 2), from a healthy individual
was used as a secondary control. All the NiPSC lines
(Supplementary Table S1) were positive for the neuronal
pluripotency marker nestin and morphologically indistinguish-
able (Supplementary Figure S1).
NiPSCs were differentiated to dopaminergic neurons (DAn)
using a 30-day two-stage protocol28 (see Materials and
Methods; Supplementary Figure S2A). The presence of
β-III-Tubulin and MAP2 (neuronal markers), Lmx1a and Nurr1
(key factors for dopaminergic specification) and TH (tyrosine
hydroxylase, a dopaminergic marker) was confirmed in the
different lines during differentiation by immunofluorescence
(Supplementary Figure S2B), demonstrating that the NiPSCs
were capable of generating DAn. Moreover, co-expression of
TH and GIRK-2 (Supplementary Figure S2B) indicated that
the DAn generated using the described protocol were mostly
of the A9 subtype, the subgroup found in the substantia nigra
pars compacta and the one most affected in PD.30
α-Synuclein is overexpressed in the SNCA_Tri lines and
further upregulated during neuronal differentiation.
SNCA gene triplication has been associated with increased
expression and aggregation of aSyn in PD patients31 and
increased levels of aSyn in NiPSCs from the SNCA_Tri lines
compared with those of control individuals.29 We quantified
the differences in protein content by immunofluorescence of
aSyn between patient and control lines at different stages of
differentiation (Figures 1a and b). Greater integrated signal
intensities (per cell) were observed in the undifferentiated
state of SNCA_Tri and the difference (∼2-fold) was even more
pronounced after differentiation (Figure 1b). aSyn expression
levels were further quantified by qRT-PCR and immunoblot
analysis (Figures 1c–e), confirming upregulation of mRNA in
the patient lines. Although neither technique assessed
heterogeneity in cellular expression, the average mRNA
abundance and the immunoblot band intensities corresponding
to the 15 kDa monomeric aSyn in the SNCA_Tri differentiated
cells were 1.8 × and 2.4 × that of the two control lines.
Surprisingly, the aSyn protein levels detected both by
immunofluorescence and immunoblotting with several anti-
aSyn antibodies were depressed during DA1 differentiation in
the presence of fibroblast growth factor 8 (FGF8) and
smoothened agonist (SAG). However, both control and
SNCA_Tri showed the expected upregulation in aSyn mRNA
and protein accumulation after DA2 differentiation to a
neuronal phenotype.32
aSyn overexpression in SNCA_Tri impairs neuronal
differentiation and maturation. The overexpression of
aSyn due to SNCA gene triplication significantly affected
neuronal progenitor cells during differentiation and matura-
tion. Upon 10 days in culture in the presence of midbrain
specification factors FGF8 and SAG (DA1 medium) cell
polarity became evident and cells from the patient and control
lines initiated the generation of neurites positive for
β-III-Tubulin and MAP2 (early neuronal markers). There were
no perceptible differences in morphology or levels of
expression of early neuronal markers between the lines
(Supplementary Figure S3). However, after re-plating the
cells at a density of 300 cells/mm2 for the second stage of
differentiation in the presence of cyclic adenosine monopho-
sphate (cAMP), brain-derived neurotrophic factor and glial
cell-derived neurotrophic factor (GDNF) (DA2 medium),
clear differences in neuronal development were observed
(Supplementary Movie 1). The cells from the control line
rapidly became post-mitotic and by day 9 in DA2, a complex
neuronal network with pronounced neurite interconnectivity
was evident. In contrast, the cells from the SNCA_Tri line
showed a tendency to migrate and form local clusters during
the first days of DA2 medium cultivation (see day 4 in
Supplementary Movie 1), after which some cells continued to
proliferate while those with an incipient neuronal appearance
failed to develop a complex network.
To focus on the influence of aSyn on the neuronal
differentiation of the patient lines, we neutralized the effects
of other genomic variability by generating RNAi SNCA
knockdowns from the two clones of SNCA_Tri using transduc-
tion with a lentivirus pLKO.1 puro vector containing an shRNA
against aSyn mRNA. Infected cells (SNCA_Tri-C1_KD
and SNCA_Tri-C2_KD) were continuously selected with
puromycin and showed lower levels of aSyn compared with
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non-targeting shRNA control (SNCA_Tri-C1_Scr) cells, which
demonstrated unaltered aSyn levels (Figure 2a).
The different lines were subjected to the differentiation
protocol in parallel and examined for expression of TH by
immunoblot and immunofluorescence (Figures 2b and c;
Supplementary Figure S4). TH+ cells appeared in all the lines,
but TH+ cell numbers were significantly lower in the SNCA_Tri
lines (TH+ cells in percentage of all cells: control 1: 8%; control
2: 7%; SNCA_Tri-C1: 0.3% and SNCA_Tri-C2: 0.4%). Knock
down of aSyn resulted in a partial recovery of the dopaminer-
gic phenotype (2% in SNCA_Tri-C1_KD and 0.8% in SNCA_
Tri-C2_KD) to a degree dependent on the knockdown level in
the two cell lines, whereas no effect was observed with the
non-targeted shRNA control (0.3%) (Figure 2d).
Attempts to upregulate aSyn in the control line by lentivirus
transduction produced highly vulnerable cells with much
higher levels of aSyn than the patient line, and which died
when subjected to the differentiation protocol. To overcome
this limitation, we used LUHMES cells that can be
differentiated rapidly and efficiently to biochemically
mature dopaminergic-like neurons.33–35 LUHMES cells
were infected with lentiviral vectors containing aSyn with
an IRES-GFP or GFP only (serving as a control). GFP-
expressing cells were selected by fluorescence-activated
cell sorting, differentiated and examined for TH expression
by immunoblotting (Figure 2f). The aSyn levels in the
aSyn overexpressing LUHMES were increased ~ 4.5-fold
compared with the GFP-infected control LUHMES
line, while TH levels were reduced more than 50-fold
(Figures 2f and g), providing further evidence that over-
expression of aSyn by either viral transduction or chromosomal
triplication impairs neuronal differentiation.
Figure 1 SNCA_Tri line overexpresses aSyn after differentiation. (a) aSyn immunofluorescence during NiPSCs differentiation (DNA counterstaining in blue).
(b) Quantification of aSyn expression by total aSyn brightness (mean background fluorescence subtracted). The 30* time point corresponds only to cells with upregulated aSyn
expression selected by image segmentation. All reported values are normalized to the number of analyzed cells. (c) SNCA mRNA abundance quantified by real-time PCR
showing an increased transcription with neuronal differentiation and higher aSyn expression in the triplication line after DA2 differentiation (n= 3). (d) Representative immunoblot
showing greater abundance of the 15 kDa monomeric aSyn in SNCA_Tri NiPSCs and differentiated cells compared with control 1. (e) aSyn quantification analysis from
immunoblots (n= 4). Statistical differences were determined by P-values of *Po0.05, **Po0.01 and ***Po0.001
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Figure 2 SNCA triplication impairs neuronal stem cell differentiation. (a) aSyn concentration determined by ELISA in protein extracts from NiPSCs. (b) Expression of tyrosine
hydroxylase (TH) determined by immunoblot after DA2 differentiation. (c) TH immunofluorescence (green) in differentiated DAn neurons. DNA counterstained with DRAQ5 (blue); Tuj1 is
represented in red (representative images from control 2, SNCA_Tri-C1-Scr, SNCA_Tri-C2 and SNCA_Tri-C2_KD lines are given in Supplementary Figure S4).
(d) Abundance of TH+ neurons expressed as a percentage of the total number of cells. Neurons were obtained from three independent differentiations and imaged at a
magnification of × 20. More than 15 000 cells were analyzed in each cell line. (e) Abundance of GABA+ neurons expressed as a percentage of the total number of cells.
Results were acquired and analyzed as described for TH+ cells. (f) Immunoblot showing aSyn and TH expression in LUHMES cells flow-sorted for expression of aSyn-IRES-GFP (aSyn
o/e) or GFP only (GFP Control). (g) TH quantification analysis of LUHMES immunoblots (n= 3). Statistical differences were determined by P-values of *Po0.05 and ***Po0.001
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We assessed whether the observed effects on differentia-
tion were specific to the dopaminergic pathway by quantitating
the fraction of GABA-positive cells after differentiation.
Differentiated NiPSCs immunofluorescently labeled for GABA
revealed values of 15% for control 1, 6.5% for SNCA_Tri and a
recovery to 10% for SNCA_Tri_KD (Figure 2e), demonstrating
that the impairment in differentiation on the triplication line and
recovery upon aSyn knockdown are neither specific nor
restricted to the dopaminergic pathway.
Electrophysiological impairment due to aSyn overex-
pression in SNCA_Tri. We characterized the membrane
properties of the differentiated lines by single-cell electro-
physiology (Figure 3; Supplementary Figure S5). Data
obtained from the cells could be categorized into three
distinctive classes according to the action potential (AP)-firing
pattern and amplitudes of the INa(V): cells that fired well-
defined APs (termed AP-firing cells); cells that generated
small and significantly slower APs (termed Spikelet-firing
cells); and cells that were not able to generate APs in
response to current injection (termed Passive cells)
(Figure 3a). The fraction of AP-firing control 1 cells was
79% and 43% in the SNCA_Tri-C1. Interestingly, when aSyn
was knocked down at the NiPSC stage, the fraction of
AP-firing cells increased to 56%. Passive cells were only
observed with SNCA_Tri (Figure 3b).
A more detailed summary of the properties of the AP-firing
cells is given in Supplementary Figure S5. The absolute peak
amplitudes of the APs for the SNCA_Tri line were lower
compared with control; the knock down of aSyn did not exhibit
a statistically significant recovery.
Voltage-gated ion conductances were also characterized.
Representative recordings of INa(V) and IK(V) are shown in the
right panels of Figure 3c. The peak of the I–V curve of INa(V)
was ∼− 10mV and the average amplitude of the INa(V)
measured at this membrane potential was −1.7± 0.3 nA for
control 1 and −0.7±0.3 nA for SNCA_Tri. aSyn knockdown in
the patient line rescued the INa(V) average amplitude by −50%
(−1.1± 0.4 nA). A similar tendency was observed for IK(V) in
the three groups (Figure 3c): smaller IK(V) in SNCA_Tri when
compared with control and a partial rescue of the IK(V)
amplitudes in the SCNA_Tri_KD.
SNCA_Tri shows reduced expression of genes associated
with signal transduction and neuronal differentiation. We
compared the gene expression profiles of several genes
associated with PD in the differentiated cells using a commercial
PCR expression array. Of the 84 genes on the PCR array, 11%
showed a statistically significant difference (Po0.05) between
the SNCA_Tri and both the control and SNCA_Tri_KD lines
(Table 1). Four of these were downregulated in the SNCA_Tri
line and represent genes directly related to neuronal cell
differentiation (DLK, GABABR2, NURR1 and TH). In addition
GIRK-2 was also downregulated in SNCA_Tri, consistent with
the lower levels of potassium currents observed by single-cell
electrophysiology and reflecting the impaired neuronal matura-
tion of SNCA_Tri line. The complete PD PCR-array gene
expression profiles of SNCA_Tri versus control or SNCA_x3_KD
are presented in Supplementary Table S2. Interestingly, no
significant differences were observed in the expression levels of
proapoptotic genes, indicating that the observed impaired
differentiation is not caused by a selective neuronal death in
the patient lines. We performed an LDH release assay on all
lines without added toxic stress in the NiPSC state and after
differentiation to assess cell fragility (Table 2). The measured
LDH release was low and similar in the different lines tested in
both stages, although all lines showed an increased LDH
release after differentiation.
aSyn overexpression in SNCA_Tri reduces neurite
outgrowth. The images in Supplementary Movie 1 demon-
strate that the SNCA_Tri line failed to develop a complex
Figure 3 Electrophysiological characterization of differentiated NiPSCs. (a)
Examples of three distinctive changes in membrane potential elicited by current injection.
AP-firing cells were distinguished from Spikelet-firing cells by two criteria: (i) the slower
kinetics of their APs measured under current clamp and (ii) the larger peak amplitudes of
their INa(V) measured under voltage clamp. Maximum rates of rise of APs, which were
obtained from the differentiated membrane potential, were generally ≥ 5 mV/ms for AP-
firing but lower for Spikelet-firing cells. Peak amplitudes of INa(V) were generally ≥ 200 pA
in AP-firing but lower in Spikelet-firing cells. In passive cells INa(V) was undetectable. (b)
Relative fraction of AP-firing, Spikelet-firing and Passive cells. (c) Characterization of INa(V)
and IK(V) in control, SNCA_Tri and SNCA_Tri_KD cells. The mean I–V relationships of INa
(V) and IK(V) are shown in the left panels. Representative recordings are shown in the right
panels for control and triplication lines. See text for details
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neuronal network during differentiation. To further investigate
the impact of the aSyn overexpression on neurite outgrowth,
differentiated NiPSCs were stained for TH and neurites were
traced (Figure 4a). The higher neuronal connectivity and
spine formation present in control compared with the
SNCA_Tri cells was perceptible at high magnification
(Figure 4b). Tracing analysis showed a significant recovery
upon aSyn knockdown in the number of neurites per cell and
in the total neurite length (Figures 4c and e), confirming that
increased aSyn gene expression had a negative impact on
the neuronal development of the SNCA_Tri line. Total DAn
neurite length per cell increased from 208 μm in the
SNCA_Tri-C1 to 394 μm in the SNCA_Tri-C1_KD and from
158 μm in the SNCA_Tri-C2 to 395 μm in the SNCA_Tri-
C2_KD (controls: 864 and 306 μm) (Figure 4c); and the
median number of neurites per cell increased from 1 in the
patient clones to 2 after aSyn knockdown (control 1: 5; control
2: 2 neurites per cell) (Figure 4e). Interestingly, the mean
length of the longest neurite (Figure 4d) and the total mean
neurite length (not shown) were indistinguishable for all the
lines. We attribute the reduced number of neurites in control 2
versus control 1 to the greater age of the control 2 individual
compared with the others (Supplementary Table S1). We also
determined the ratio of the maximum number of branches to
the number of primary neurites, the Schoenen Ramification
Index36 (Figure 4f), an estimate of the degree of arborization
of a single neuron. No statistically significant differences were
observed between the lines. Thus, the significant rescue of
the number of neurites and total neurite length upon aSyn
knockdown constitutes primary evidence that overexpression
of aSyn significantly impairs neurite outgrowth in the NiPSCs-
derived neurons.
All neurite outgrowth measurements were performed on
cells that had been induced to differentiate for a total of
30 days. To rule out the possibility that the SNCA_Tri line
required a longer time to develop its neuronal network than the
control line, the time of differentiation was extended to a total of
64 and 75 days. Extensive interconnected neurons were
evident in the control line whereas a lower and less robust
neurite connectivity appeared in the SNCA_Tri line
(Supplementary Figure S6).
aSyn overexpression in SNCA_Tri leads to increased
autophagic flux. Impaired neurite outgrowth has been
associated recently with dysregulation of autophagy.37,38 To
investigate whether aSyn accumulation in the SNCA_Tri line
directly impacts macroautophagic flux, we determined the
numbers of LC3+ autophagosomes in cells treated with
chloroquine, a known blocker of autophagy that inhibits the
fusion between autophagosomes and lysosomes.39 The
difference between LC3 puncta in the presence and absence
of chloroquine provides an estimation of the autophagic flux.
Higher activity leads to a greater accumulation of LC3-II after
chloroquine treatment.29 Counts of LC3+ puncta showed that
the autophagic flux was comparable between the different
cell lines in the NiPSCs stage. However, after differentiation
and the accompanying upregulation of aSyn, the SNCA_Tri
line showed increased macroautophagy compared with both
the control and SNCA_Tri_KD lines (Figures 5a and b).
Discussion
We have investigated NiPSC lines derived from a PD patient
with a triplication of the SNCA locus and found a negative
impact of increased expression of human WT aSyn on
neuronal differentiation. This determination was made by
comparison of the patient-derived SNCA_Tri line (2 clones)
with KD lines generated by knocking down aSyn in the
SNCA_Tri with a lentivirus shRNA vector, thereby circumvent-
ing phenotypic differences emerging from genetic variability
when comparing different lines. A line derived from an
age-matched healthy sibling was used as a standard control
and some experiments were augmented by an additional
control line from an older healthy individual lacking a known
PD mutation.
We recently reported an increased stress vulnerability of
NiPSCs from the two clones of SNCA_Tri compared with
Table 1 Differential expression of Parkinson’s disease-related genes in SNCA_Tri-C1, control 1 and SNCA_Tri-C1_KD lines
Gene
symbol
Gene
name
Gene description Fold change
SNCA_Tri versus
control 1
P-value Fold change
SNCA_Tri versus
SNCA_Tri_KD
P-value Function
DLK1 DLK Delta-like 1 homolog
(Drosophila)
−1.65 0.017 −1.36 0.006 Signal transduction
GABBR2 GABABR2 γ-Aminobutyric acid B
receptor
− 3.60 0.022 −2.96 0.018 Signal transduction
HSPA4 HS24 Heat shock 70 kDa protein 4 1.32 0.003 1.13 0.032 Heat shock response
KCNJ6 GIRK-2 K inwardly rectifying channel − 3.17 3.1 × 10− 5 −2.59 3.1 × 10− 4 Ion transport
NR4A2 NURR1 Nuclear receptor subfamily 4,
group A, member 2
− 7.79 0.030 −3.97 0.040 Signal transduction
SNCA PARK1 α-Synuclein 1.85 0.029 4.68 0.005 –
TH TYH Tyrosine hydroxylase −10.16 8.8 × 10− 5 −5.54 4.2 × 10− 4 Signal transduction
TPBG M6P1 Trophoblast glycoprotein − 2.13 0.008 −2.21 0.008 Cell adhesion
YWHAZ YWHAD Tyrosine 3-monooxygenase 1.07 0.005 1.18 0.003 Inflammation
Table 2 Cytotoxicity levels at the NiPSC stage and after differentiation (n= 3,
mean±S.E.M.)
NiPSCs DA2
control 1 4.2±0.4 5.9± 0.7
SNCA_Tri-C1 3.2±0.3 7.5± 0.4
SNCA_Tri-C1_KD 3.5±0.2 6.8± 0.5
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SNCA_Tri_KD_C1 and controls 1 and 2 used in this study.29
Although under high-glucose growth conditions the lines
showed little difference in viability, upon starvation or treat-
ment with toxicants the NiPSCs from the two SNCA_Tri clones
displayed significantly increased apoptosis, delayed protein
import to organelles and reduced catabolism of aggregated
proteins compared with the control lines. These data indicate
that the increased expression of aSyn in the patient lines
resulted in neuronal precursor cells with reduced metabolic
plasticity and reduced energy capacity. The focus of the
Figure 4 SNCA triplication reduces neurite outgrowth. (a) Neurite morphology of dopaminergic neurons from control 1, SNCA_Tri-C1, SNCA_Tri-C1_KD, SNCA_Tri_C2, and
SNCA_Tri-C2_KD differentiated NiPSCs, identified by TH immunocytochemistry. (b) High magnification images of neurite morphology in the patient and control lines: MAP2
(green) and Lmx1A (red) (c–f) Quantification of dopaminergic neurite morphology per cell in terms total neurite length (c), mean length of the longest neurite (d), number of
neurites (e) and Schoenen Ramification Index (f). The data are shown in scatter box plots representing the median and interquartile range of each group and explicitly explained in
the Results. Statistical differences were determined by P-values of *Po0.05, **Po0.01 and ***Po0.001
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present study was to determine how these lines were able to
cope with the challenges posed by differentiation, a process of
extensive cell remodeling that requires robust catabolic
activity and ample energy reserves.
Both the control and SNCA_Tri lines showed the presence
of the early neuronal markers Tuj1 and MAP2, and key factors
for dopaminergic specification such as Lmx1a, Nurr1 and TH.
However, the differentiation efficacy of the two independent
SNCA_Tri clones was dramatically lower compared with
the control lines, a result that corroborates the report that
viral overexpression of aSyn in human neural progenitor cells
leads to decreased levels of TH+ and GABA+ neurons.40
Figure 5 SNCA triplication increases macroautophagy in differentiated neurons. NiPSCs and differentiated neurons pretreated with vehicle or chloroquine (5 μM) for 18 h
prior to fixation and immunofluorescence analysis. (a) Macroautophagy flux determined by LC3 immunostaining (green) in the presence (+) or absence (− ) of chloroquine. DNA
was counterstained with DRAQ5 (blue). (b) Quantification of the intraneuronal LC3+ puncta per cell (450 cells per line analyzed in the NiPSCs stage and4100 cells in the DA2
stage). Blue arrows designate the differences in LC3+ autophagosomes between the cells pretreated with chloroquine and vehicle, and are used as an estimation of the
macroautophagic flux. Statistical differences were determined by P-values of *Po0.05, **Po0.01 and ***Po0.001
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Knockdown of aSyn in both SNCA_Tri lines resulted in a
rescue of the efficiency of differentiation in both lines, which
correlated with the level of knockdown. The inherent clonal
variability between different lines resulting from epigenetic
reprogramming, which we and others22,41 have observed, may
result in significant differences in iPS differentiation efficien-
cies. Other factors related to gene expression regulating cell
fate and differentiation arising from different genetic back-
grounds may also compensate the impact of elevated aSyn
inasmuch as the gene triplication event in the patients was not
restricted to the SNCA locus. In the patient featured in this
study, the SNCA triplication event corresponded to a 1.61–
2.04Mb region of chromosome 4 with at least 17 annotated
genes.42 Nonetheless, the significant recovery after aSyn
knockdown suggests the existence of a direct correlation
between aSyn accumulation and neuronal differentiation. This
conclusion is supported by the finding that overexpression of
WT aSyn in LUHMES cells also significantly reduced TH
levels after differentiation. Taken together, the results indicate
a negative effect of aSyn overexpression and pathological
accumulation on neuronal commitment and differentiation.
A possible feature leading to impaired neuronal differentia-
tion of the SNCA_Tri line is aSyn-induced transcriptional
dysregulation of genes involved in neuronal development. We
compared SNCA_Tri-C1 to its knockdown line and control 1 in
order to reveal the consequences of increased aSyn expres-
sion and minimize the effects of genetic differences between
the siblings. The PD expression array revealed changes in
nine genes, including downregulation of four genes intimately
related to neuronal differentiation and specification: NURR1,
DLK1, TH, GABBR2 and GIRK-2. Nurr1 is critical for the
development and maintenance of midbrain neurons. Thus,
loss of Nurr1 function early during development in mice leads
to the absence of midbrain neurons, while reduction of Nurr1
function in adulthood leads to a slowly progressive loss of
striatal dopamine and markers of DAn.43 Furthermore, over-
expression of aSyn in nigral DAn in rats is correlated with
reduced expression of Nurr1 and its downstream targets.44
DLK1 is a member of the Delta/Notch protein family and
participates in the specification of ventral midbrain DAn.45
DLK1 treatment during expansion of progenitor cells resulted
in increased neurons expressing TH.45 Interestingly, DLK1
has also been reported to be a Nurr1 downstream target.46
Another gene shown to be downregulated in the triplication
line is the potassium channel GIRK-2, supporting our
electrophysiology results and also pointing to reduced
neuronal maturation in the patient line.
Markedly different electrophysiological profiles of the
various cell lines were observed by a single-cell patch-clamp.
Passive, unresponsive cells were only found in the SCNA_Tri
line, whereas the control and SNCA_Tri_KD lines showed
higher numbers of AP-firing cells. In addition, INa(V) and IK(V)
currents were higher in the SNCA_Tri_KD and control 1
compared with SNCA_Tri. We conclude that reduced numbers
of ion channels are present in differentiated SNCA_Tri, leading
to smaller current amplitudes as a result of a lower neuronal
maturation of SNCA_Tri. The SNCA_Tri cells had persistently
less connectivity than the control cells after differentiation for
64–75 days (Supplementary Figure S6), and the loss of
connectivity was already manifested at 30–35 days.
A significant phenotypic feature ofSNCA triplication was the
impairment of neurite outgrowth. Neurite tracing analysis
showed that knock down of aSyn increased both the total
neurite length and the number of neurites in TH+ neurons
compared with SNCA_Tri. Interestingly, the mean neurite
length and the Schoenen ramification index were comparable
between all the lines, suggesting that aSyn can have a
negative impact on the initiation of neurite formation, but not on
its elongation and branching. Previous publications report
contrasting findings on the effects of aSyn on neurite
outgrowth. Liu et al.47 reported that aSyn promotes neurite
growth in cultured primary neurons, whereas other
investigators48–50 have shown a negative impact of aSyn on
neurite outgrowth. A fundamental difference between these
studies is the choice of the cellular models used to investigate
the effects of aSyn.Whereas in the first study the authors used
fully developed and mature rat cortical primary neurons in
culture, in which neurite outgrowth is primarily regulated by the
polymerization of cytoskeleton proteins (mainly tubulin), the
other studies reported aSyn-associated deficits on neurite
outgrowth in the context of differentiation and maturation of
newly formed neurons from progenitor cells. Recently, we
showed that aSyn has deleterious effects on the neurite
outgrowth of primary midbrain neurons48 and in another study
it was proposed that aSyn might modulate neurite outgrowth
by negatively affecting spectrin beta non-erythrocyte 1, a
protein that promotes neurite formation in differentiating SH-
SY5Y cells.51
Reduction of neurite outgrowth can occur with upregulation
of autophagy.6,7 Previous publications have reported contra-
dictory findings on the effects of aSyn accumulation on this
process.52 The apparent discrepancies in the literature may
reflect the inherent staged,53 inverse54 correlation between
disease progression and protein quality control, and also the
particular model systems employed, which vary in aSyn
expression, post-translational modification and the kind and
degree of association/aggregation. Autophagic flux was
significantly increased in the SNCA_Tri line compared with
both control and SNCA_Tri_KD lines after differentiation (i.e.
after aSyn upregulation). Similar results were found in primary
midbrain neurons, where overexpression of aSyn WT also
resulted in increased autophagic flux.48 Upregulation of
autophagy may act as a cellular compensation mechanism
to clear accumulated monomeric aSyn, although it may also
foster unspecific degradation of essential proteins and
organelles including mitochondria, thereby contributing to
the development of pathology. Under stress conditions or in
the presence of proteolysis-resistant forms of aggregated
aSyn, autophagy may be compromised.55
A number of PD-associated genes have been implicated in
neuronal development, such as SNCA, NURR1, PITX3,
PINK1, LRRK2 and VPS35,56 and progenitor cells isolated
from human brains with idiopathic PD appear to lack key
factors required for neuronal differentiation.57 We propose that
the differentiation deficits of the SNCA_Tri NiPSCs observed in
this study may reflect functional de-differentiation (loss of
function) undergone by neurons affected in and by PD over an
extended period of time, whereas compensatory and neuror-
egenerative processes in the brain impede or at least delay the
development of overtly clinical disease. The patient iPSCs
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were derived from a patient exhibiting clinical manifestations of
PD and thus chronically exposed to the effects of SNCA gene
triplication. In fact, a recent report found high levels of aSyn in
the epidermis of PD patients but no expression in control
subjects, emphasizing the systemic nature of the disease.58
Our results are consistent with a model in which genetic
variants affecting aSyn expression modulate cellular suscept-
ibility to neurodegeneration in PD, as has been proposed
recently.59,60 We also note that the procedures required to
achieve differentiation in vitro necessarily involve numerous
and complex epigenetic transformations, only some of which
may reproduce the natural pathogenetic evolution in the
disease context. Optimized, rational therapeutic regimens,
which to date are essentially empirical, need to address both
the underlying cellular processes at the molecular level35,61 as
well as the systemic mechanisms operating within the
complex environment of the central nervous system. Of direct
relevance in this connection is the recent identification of
elevated mitochondrial bioenergetics (higher basal level of
oxidative phosphorolyation, greater axonal mitochondrial
density) and high complexity of axonal arborization as major
contributors to the hightened vulnerability of nigral dopamine
neurons to toxic agents.62 The neuroenergetic issues high-
lighted by the present and related studies also lend support for
a major role of metabolic reprograming in neuropathogenesis,
proposed by Demetrius et al. (reviewed in Demetrius et al.63)
as an alternative to the amyloid hypothesis in the context of
Alzheimer’s disease and invoked here for PD. It is postulated
that age-induced mitochondrial dysfunction leads to an
upregulation of the complementary metabolic processes of
oxidative phosphorylation (inverseWarburg effect) in neuronal
mitochondria and of glycolytic activity (Warburg effect) in the
cytoplasm of astrocytes. The short- and long-range neuron–
astrocyte cytoarchitecture is envisioned as key in mediating
both supportive as well as competitive interactions between
disease-affected and normal neurons and astrocytes. Muta-
tion or overexpression of aSyn – as in the case of the patient
NiPSCs of this study and/or the result of reduced degradation
– can thus be regarded as factors initially exacerbating age-
related mitochondrial dysregulation at the level of individual
neurons,64 and subsequently promoting disease progression
by virtue of resource depletion (a process of ‘natural
selection’63) engendered by the pathological neurons.
Materials and Methods
Generation and differentiation of patient-derived iPSCs. Fibroblast
biopsies from a patient with early onset PD carrying a triplication of the SNCA locus
and a four-year older mutation-negative healthy female sibling were used to
generate iPS cells by The Parkinson’s Institute.26 Recently published protocols
combining neuronal induction from embryoid bodies and dual SMAD inhibition
combined with PSA-NCAM magnetic-bead sorting were used to generate
neuroprogenitor cell lines, NiPSC.27 NiPSCs were seeded at 5 × 102 cells/mm2
on culture dishes coated with Geltrex (Life Technologies, Darmstadt, Germany,
#A1413302), and propagated in NiPSCs growth medium: MACS Neuro Medium
(Miltenyi Biotech, Bergisch Gladbach, Germany, #130-093-570), 1 × MACS
NeuroBrew-21 (Miltenyi Biotech #130-093-566), 2 mM L-glutamine (Life Technolo-
gies #25030024), 1 × NEAA (Life Technologies #111400), 50 U/ml penicillin/
streptomycin (Life Technologies #15140122), 5000 U/ml ESGRO (LIF) (Merck-
Millipore, Darmstadt, Germany, #ESG1106) and 20 ng/ml bFGF (PeproTech,
Hamburg, Germany, #AF-100-18B-50) for up to 25 passages. The cells were
passaged at confluency with Accutase (Life Technologies #A1110501) and
reseeded in a new dish for propagation or differentiation.
Differentiation into DAn was performed in a two-step process, in which 5 × 102
cells/mm2 were first incubated for 10 days in DA1 medium: MACS Neuro Medium, 1 ×
MACS NeuroBrew-21, 2 mM L-glutamine 1 × NEAA, 50 U/ml penicillin/streptomycin,
recombinant human-FGF-8a (R&D Systems, Wiesbaden-Nordenstadt, Germany,
#4745-F8) and 1 μM smoothened agonist SAG (Merck-Millipore #566660). At 10–
11 days cells were reseeded at 8–10 × 102 cells/mm2 and incubated for a minimum
period of at least 20 days in the second differentiation medium, DA2: MACS Neuro
Medium, 1 × MACS NeuroBrew-21, 2 mM L-glutamine 1 × NEAA, 50 U/ml penicillin/
streptomycin, 20 ng/ml recombinant human GDNF (Peprotech, Rocky Hill, NJ, USA,
#450-10), 25 ng/ml recombinant human-BNDF (R&D Systems #248-BD) and 1 mM
dibutyryl-cAMP (Sigma Aldrich, Taufkirchen, Germany, #D0627).
For immunofluorescence microscopy and electrophysiology, cells were seeded on
10 or 12 mm diameter coverslips previously coated with 20 μg/ml poly-L-lysine
(Sigma Aldrich #P7890) and 20 μg/ml laminin (Sigma Aldrich #L2020).
Culture and Differentiation of LUHMES cells. Proliferating LUHMES
cells were maintained and differentiated according to Scholz et al.35 LUHMES cells
used in this paper were selected by fluorescence-activated cell sorting for GFP
expression after infection by a WP1 Lentivirus containing the human cDNA for aSyn
and an IRES-GFP sequence (see below). Proliferation medium consisted of DMEM/
F12 (Life Technologies #12634010), 2 mM L-glutamine (Sigma Aldrich #G7513), 1x
N2 supplement (Life Technologies #17502-048) and 40 ng/ml recombinant human
basic FGF (R&D Systems #4114-TC-01M). Proliferating cells were cultured to a
confluence of 80%, and then dissociated with trypsin (138 mM NaCl, 5.4 mM KCl,
6.9 mM NaHCO3, 5.6 mM D-glucose, 0.54 mM EDTA, 0.5 g/l trypsin from porcine
pancreas type IX-S; Sigma Aldrich #T-0303) and seeded into a T175 Nunclon flask
at a density of 8 × 106 cells/flask, containing proliferation medium. After 24 h,
proliferation medium was removed and replaced with differentiation medium,
consisting of DMEM/F12, 2 mM L-glutamine, 1 × N2 supplement, 1 mM dibutyryl-
cAMP (Sigma Aldrich #D0627), 2.25 μM tetracycline (Sigma Aldrich #T7660) and
2 ng/ml recombinant human GDNF (R&D Systems #212-GD-050). Forty-eight hours
after the medium change, cells were trypsinized and seeded into Nunc 24-well
plates at a density of 250 000 cells/well, in 1 ml of differentiation medium/well. At
72 h after seeding one-half of the differentiation medium was refreshed. All flasks
and plates were precoated with 50 μg/ml poly-L-ornithine (Sigma Aldrich #P3655)
and 1 μg/ml fibronectin (Sigma Aldrich #F1141) for 24 h at 37 °C and air dried prior
to seeding of cells.
Immunofluorescence. Cells were fixed with 3.7% paraformaldehyde (PFA) in
Tyrode’s buffer at room temperature for 15 min and subsequently washed with
10 mM Tris-HCl, pH 7.4 saline buffer, to block PFA activity. Cells were then blocked
in PBS with 0.1% Triton-X100 and 0.5% BSA or 2 mg/ml of donkey serum (when
using donkey anti-goat secondary antibodies). The primary antibodies used are
listed in Supplementary Table S3. The following secondary antibodies: Cy3-
conjugated donkey anti-goat F(ab)2 (Dianova, Hamburg, Germany); Cy5-conjugated
donkey anti-goat IgG (Abcam, Cambridge, UK); Oregon Green 488-conjugated goat
anti-rabbit IgG (Life Technologies); and Alexa Fluor 546-conjugated goat anti-mouse
F(ab)2 (Life Technologies) were all used at a 1:2000 dilution in blocking solution.
Images were acquired using a Zeiss LSM 510 Meta confocal microscope, except for
the TH+ cell quantifications where the images were acquired with an Andor
Revolution XDi Spinning Disk Confocal System.
Real-time PCR analysis. Total mRNA was isolated with RNeasy Mini Kit
(Qiagen, Venlo, Netherlands, #74104), following the manufacturer’s instructions.
One microgram was used to synthetize cDNA (20 μl reaction volume) using the
Omniscript reverse transcriptase kit and oligo-dt primers (Qiagen, # 205111 and
#79237) in a Thermo Hybaid PCR Express (Fischer Scientific, Schwerte,
Germany). Real-time PCR analyses of 1 μl of the cDNA products were performed
in duplicate with iQ SYBR Green Supermix (Bio Rad, Munich, Germany, #170-8882)
in a CFX96 Real time system Thermal cycler (Bio Rad). The primer pairs used for
real-time amplification of aSyn are described in Rhinn et al.59 Primers for HPRT41
and QuantiTect Primer assay GAPDH mix (Qiagen #QT00079247) were used for
normalization. Relative expression levels were calculated with subsequent ΔCT
values that were assessed using the comparative CT method with subsequent ΔCT
values normalized to the housekeeping genes HPRT and GAPDH.
Gene expression profiling. One microgram of mRNA (isolated as described
above) was converted to cDNA using the RT2 First Strand Kit (SABiosciences,
Venlo, The Netherlands, # 330401). Real-time PCR analysis was performed using
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the RT2 Profiler Human Parkinson’s disease PCR Array (SABiosciences
#PAHS-124ZD-12) according to the manufacturer’s instructions on a CFX96 Real-
Time PCR system (Bio Rad). Gene of interest (GOI) CT values were normalized
to the average CT value of five housekeeping genes (β-actin (ACTB),
β-2-microglobulin (B2M), glyceraldehyde-3-phosphate (GAPDH), hypoxanthine-
guanine phosphoribosyltransferase (HPRT) and ribosomal protein, large,
P0 (36-B4)), and subsequent ΔCT values are expressed as fold change,
2−ΔCT(SNCA_x3)/2−ΔCT(Control or SNCA_x3_KD). Fold regulation was calculated
as −1/2−ΔCT for all negative fold changes.
Protein extraction and immunoblot analysis. NiPSCs and LUHMES
were resuspended with Accutase or trypsin, respectively, washed with Tyrode’s
buffer, and lysed with buffer containing 50 mM Tris, 1% Triton, 250 mM NaCl, 5 mM
EDTA supplemented with 1 mM PMSF and 1 × protease inhibitor cocktail (Roche
Applied Science, Penzberg, Germany, #11873580001) for 30 min on ice.
Subsequently, the extracts were centrifuged at 20 000 × g, at 4 °C, for 30 min.
The supernatant was then collected and the protein concentration was measured
with a bicinchoninic acid assay (Fischer Scientific #23227). The same amount of
total protein for each cell lysate was loaded onto NuPAGE Novex System Bis-Tris
4–12% gels with MES (2-(N-morpholino) ethanesulfonic acid)-SDS buffer (Life
Technologies # NP0336BOX and # NP0002, respectively). After electrophoresis, and
transfer onto polyvinylidene difluoride membranes, specific protein bands were
detected using appropriate primary and secondary antibodies (mAB anti-aSyn;
1 : 1000), rAB anti-TH (Merck-Millipore #AB152; 1 : 5000), and horseradish
peroxidase goat anti-mouse (Dianova #111-036-003) and goat anti-rabbit (Dianova
#111-035-003) secondary antibodies, followed by SuperSignal West Pico
Chemiluminescent Substrate (Fischer Scientific #34077). The signals were recorded
on X-ray films (GE Healthcare, Buckinghamshire, UK, #28906837) using a Kodak
X-OMAT 2000 Processor, and quantified with the gel analysis tool of Fiji analysis
software.65 For the loading control, the membranes were re-probed with a mAb anti-
α-tubulin (a kind gift from Dr. Mary Osborn) or an mAB anti-β-actin (Ambion,
Darmstadt, Germany, #AM4302, 1 : 5000). The results are expressed as a ratio of
the aSyn and α-tubulin, or TH and β-actin signals. Total aSyn quantification by
ELISA was performed using the Human alpha-Synuclein ELISA Kit (Life-
technologies #KHB0061) following the manufacturer’s protocol. Data obtained from
the ELISA were then normalized to total protein.
Lentivirus. Constructs: Full-length human aSyn cDNA (SNCA, gene association
NM000345) was subcloned into a second-generation lentiviral vector pWPI
(Tronolab, Lausanne, Switzerland), followed by an IRES-GFP sequence, and the
original vector promoter (EF1α) was replaced by the chicken β-actin promoter. A
vector containing only the IRES-GFP cassette was used for control experiments.
For lentiviral shRNA production the third-generation vector pLKO.1 puro (Sigma
Aldrich) containing the sequence 5′-ACCAAAGAGCAAGTGACAAAT-3′ (clone ID,
TRCN0000003736) was used to knock down human aSyn gene expression. Control
experiments were performed using the same vector containing the non-target
shRNA sequence 5′CCTAAGGTTAAGTCGCCCTCG3′. All cloned sequences were
verified by automated sequencing (StartSeq, Mainz, Germany).
Lentivirus generation and transgene expression: Second-generation lentiviral
particles were generated as previously described.66 Briefly, the modified transfer-
vectors were purified and co-transfected with the packaging vectors (Tronolab,
Switzerland) into 293 FT cells (Life Technologies) for 48 h. The supernatant was
collected, concentrated by PEG-it Virus Precipitation Solution (Systems Biosciences,
Heidelberg, Germany) and resuspended in Panserin 401 (PAN, Germany).
Transgene expression was determined by qRT-PCR using SYBR GREEN after
infection of the 293-HEK cells using specific primers to the woodchuck hepatitis virus
post-transcriptional regulatory element (WPRE) as described.67 Virus were used at
the same infectivity in all applications and stored at − 80 °C. NiPSCs were infected
with the pLKO.1 containing the shRNA and non-target sequences at 50–70% cell
confluency. Cells were washed with NiPSCs medium after 24 h and selected with
3 μM puromycin after 48–72 h.
Electrophysiology. Patch-clamp recordings were made from NiPSCs at
45 days of differentiation by using an EPC-10 amplifier controlled by Pulse software
(HEKA Elektronik, Lambrecht/Pfalz, Germany). Sampling intervals and filter settings
were 20 μs and 4.5 kHz, respectively. Cells were visualized by differential
interference contrast microscopy through a × 60 water-immersion objective (NA
1.0), (Olympus, Darmstadt, Germany) using an Axioskop FS microscope (Zeiss,
Germany). All experiments were performed at room temperature. Patch pipettes
were prepared from borosilicate glass (Science Products GmbH, Hofheim am
Taunus, Germany) and pulled on a P-97 micropipette puller (Sutter Instrument,
Novato, CA, USA) with an open tip resistance ranging from 4–6 MΩ. Pipettes were
coated with dental wax to minimize fast capacitive transients during voltage-clamp
experiments and to reduce stray capacitance. Access resistance (Rs) values were
≤ 20MΩ. Rs compensation was set to 60–70% (10 μs delay) during voltage-clamp
experiments. Patch pipettes were filled with a solution containing: 100 mM
potassium gluconate, 60 mM KCl, 10 mM HEPES, 0.5 mM EGTA, 5 mM Na2-
phosphocreatine, 4 mM ATP-Mg, 0.3 mM GTP, set at pH 7.3 with KOH. The
standard extracellular recording saline solution contained: 125 mM NaCl, 2.5 mM
KCl, 10 mM glucose, 25 mM NaHCO3, 1.25 mM NaH2PO4, 2 mM CaCl2, and 1 mM
MgCl2, 0.4 mM ascorbic acid, 3 mM myo-inositol, and 2 mM Na-pyruvate at pH 7.3
when bubbled with carbogen (95% O2, 5% CO2).
Sodium (INa(V)) and potassium (IK(V)) currents were evoked by step depolarizations
(50 and 100 ms) from a holding potential of − 70 mV with 10 mV increments up to
+40 mV. Recordings with leak currents4100 pA were excluded from the analysis.
APs were measured in the current-clamp mode of the EPC-10 after carefully
adjusting the fast-capacitance cancellation in cell-attached mode. The membrane
potential was adjusted to − 70 mV in all current-clamp recordings by injecting a small
hyper or depolarizing current. APs were elicited by depolarizing current injections,
starting from − 20 to 170 pA in 10 pA increments. In all the three cell lines, INa(V) was
completely blocked after addition of 2 μM tetrodotoxin to the bath solution (data not
shown). Offline analysis was performed with ‘IgorPro’ software (Wavemetrics,
Portland, OR, USA).
Cytotoxicity. Cytotoxicity was assessed in NiPSCs and differentiated neurons
using the LDH cytotoxicity detection kit (Roche Applied Science #11644793001).
Culture media were collected from the cells of interest (n= 3 independent wells)
and the LDH activity was determined following the manufacturer’s protocol. Results
are expressed as the percentage of total LDH activity determined in parallel wells
after total cell lysis (n= 3). The results were measured in a PHERAstar FS plate
reader (BMG Labtech, Offenburg, Germany).
Neurite tracing. Neurite outgrowth was assessed in DAn, which were identified
by immunofluorescence using an anti-TH antibody (Supplementary Table S2). The
length of each dendritic segment was determined by tracing the center of the
dendritic shaft, using the Autopath method available in the Filament Tracing Tool
from Imaris v7.6.1. For each neuron, the number of neurites originating from the
soma, the individual length of the longest single neurite, and the total length of all
neurites in one neuron, were determined. A Schoenen ramification index36 for each
neuron was then calculated by dividing the maximum number of neurites by the
number of primary neurites, i.e. the number of neurites arising directly from
the soma.
Autophagy. NiPSCs and differentiated neurons were incubated to determine the
macroautophagy flux with vehicle or chloroquine (5 μM) for 18 h in NiPSCs growth
medium or DA2 medium, respectively, supplemented with 1 × B-27 minus anti-
oxidants (Life Technologies, #10889-038) instead of 1 × MACS NeuroBrew-21, prior
to fixation and immunostaining with anti- LC3 antibody (Supplementary Table S2).
Confocal images were obtained at x63 magnification, segmented by thresholding to
include only the LC3 signal within the autophagosomes which represents the LC3-II
fluorescent component.68 Using Imaris analysis software, the number of LC3+
puncta per cell was estimated. The minimum size of each punctum was defined as
0.2 μm2. The autophagic flux was represented as the difference of the number of
LC3 puncta for each cell line in the presence and absence of chloroquine.
Statistical analysis. Statistical analyses were performed using the GraphPad
PRISM 5 software. Values are expressed as mean±S.E.M. Statistical significance
was tested by either one- or two-way ANOVA with a Bonferroni post-test, except for
the neurite outgrowth experiments in Figure 4, where statistical significance was
tested using a one-way ANOVA with the non-parametric Kruskal–Wallis test followed
by a Dunns post-test for multiple comparisons. Statistical differences were
determined by P-values of *Po0.05, **Po0.01, and ***Po0.001.
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